1Pai VB, Nahata MC. Cardiotoxicity of chemotherapeutic agents:incidence, treatment and prevention. Drug Saf, 2000,22 (4):263-302.
2Duquaine D, Hirsch GA, Chakrabarti A, et al. Rapid-onset endothelial dysfunction with adriamycin: evidence for a dysfunctional nitric oxide synthase. Vasc Med, 2003,8 (2) : 101-107.
3Li T, Singal PK. Adriamycin-induced early changes in myocardial antioxidant enzymes and their modulation by probucol.Circulation, 2000,102(17):2105-2110.
4Wang S, Konorev EA, Kotamraju S, et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms, intermediacy of H (2) O (2)- and p53-dependent pathways. J Biol Chem, 2004, 279(24):25535-25543.
5Sawyer DB, Fukazawa R, Arstall MA, et al. Daunorubicininduced apoptosis in rat cardiac myocytes is inhibited by dexrazoxane. Circ Res, 1999, 84(3):257-265.
6Minotti G, Recalcati S, Mordente A, et al. The secondary alcohol metabolite of doxorubicin irreversibly inactivates aconitase/iron regulatory protein-1 in cytosolic fractions from human myocardium. FASEB J, 1998, 12(7):541-552.
7Estevez MD, Wolf A, Schramm U. Effect of PSC 833, verapamil and amiodarone on adriamycin toxicity in cultured rat cardiomyocytes. Toxicol In Vitro, 2000,14 ( 1 ) : 17-23.
8Weilbach FX, Chan A, Toyka KV, et al. The cardioprotector dexrazoxane augments therapeutic efficacy of mitoxantrone in experimental autoimmune encephalomyelitis. Clin Exp Immunol,2004,135(1):49-55.
9Von Hoff DD, Layard MW, Basa P, et al. Risk factors for doxorubicin-induced congestive heart failure. Ann Intern Med,1979,91(5) :710-717.
10Safra T. Cardiac safety of liposomal anthracyclines. Oncologist,2003, 8(2):17-24.
